- Home
- ORC vs MNMD Comparison
ORC vs MNMD Comparison
Compare ORC & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORC
- MNMD
- Stock Information
- Founded
- ORC 2010
- MNMD 2019
- Country
- ORC United States
- MNMD United States
- Employees
- ORC N/A
- MNMD N/A
- Industry
- ORC Real Estate Investment Trusts
- MNMD Pharmaceuticals and Biotechnology
- Sector
- ORC Real Estate
- MNMD Health Care
- Exchange
- ORC Nasdaq
- MNMD Nasdaq
- Market Cap
- ORC 1.0B
- MNMD 960.2M
- IPO Year
- ORC 2013
- MNMD N/A
- Fundamental
- Price
- ORC $7.23
- MNMD $14.20
- Analyst Decision
- ORC Hold
- MNMD Strong Buy
- Analyst Count
- ORC 2
- MNMD 7
- Target Price
- ORC N/A
- MNMD $26.71
- AVG Volume (30 Days)
- ORC 5.8M
- MNMD 2.1M
- Earning Date
- ORC 10-23-2025
- MNMD 11-06-2025
- Dividend Yield
- ORC 19.92%
- MNMD N/A
- EPS Growth
- ORC N/A
- MNMD N/A
- EPS
- ORC 0.57
- MNMD N/A
- Revenue
- ORC $80,187,000.00
- MNMD N/A
- Revenue This Year
- ORC $75.23
- MNMD N/A
- Revenue Next Year
- ORC $53.72
- MNMD N/A
- P/E Ratio
- ORC $12.60
- MNMD N/A
- Revenue Growth
- ORC 5.93
- MNMD N/A
- 52 Week Low
- ORC $5.69
- MNMD $4.70
- 52 Week High
- ORC $9.01
- MNMD $14.43
- Technical
- Relative Strength Index (RSI)
- ORC 45.82
- MNMD 68.58
- Support Level
- ORC $7.40
- MNMD $12.60
- Resistance Level
- ORC $7.78
- MNMD $13.74
- Average True Range (ATR)
- ORC 0.15
- MNMD 0.92
- MACD
- ORC -0.02
- MNMD 0.03
- Stochastic Oscillator
- ORC 12.70
- MNMD 91.99
About ORC Orchid Island Capital Inc.
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).